Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome

New Drug Approvals

マボグルラントFile:Mavoglurant.svg

ماووگلوران

Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome.[1] It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).[2]

Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials.[1][3] If successful, it would be the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.[4]

 

  1. P. Cole (2012). “Mavoglurant”. Drugs of the Future37 (1): 7–12. doi:10.1358/dof.2012.37.1.1772147. 
  2. Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). “AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease42 (3): 311–7. doi:10.1016/j.nbd.2011.01.022. PMID 21316452. 
  3.  Jacquemont…

View original post 441 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s